Drug profile · INN
briakinumab
OZESPA
briakinumab (OZESPA) is a interleukin-23 inhibitor.
EMA: application withdrawn Antineoplastic and immunomodulating agents (L04) L04AC09
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — briakinumab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
briakinumab (OZESPA) is a interleukin-23 inhibitor.
Key facts
INN briakinumab
Brand OZESPA
Mechanism Interleukin-23 inhibitor
Target Interleukin-12
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AC09
Mechanism of action
Interleukin-23 inhibitor
Primary target: Interleukin-12
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is briakinumab?
briakinumab (OZESPA) is a interleukin-23 inhibitor.
What is the brand name for briakinumab?
OZESPA is a marketed brand name for briakinumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.